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INTRODUCTION
Hereditary angioedema (HAE) is a rare condition with an esti-
mated incidence of 1/10,000 to 1/50,000 in Western countries. 
Uncontrolled activation of the classical complement pathway is 
the key mechanism of HAE.
1 There are three reported types of 
HAE,
2 whereas acquired angioedema is most frequently associ-
ated with lymphoproliferative and autoimmune disorders or 
with some medications such as ACE inhibitors and plasmin ac-
tivators.
3 Typically, patients with HAE present with recurrent 
severe angioedema of the face and upper and lower extremities 
together with abdominal pain and laryngeal edema, which is 
sometimes life threatening, and there is usually a family histo-
ry.
2-5 No gender or race predominance has been described.
6
There have been a few reports of HAE in Asia.
5,7 This is the first 
case report of HAE in Vietnam.
CASE REPORT
The patient, a 40-year-old man, had a 16-year history of recur-
rent weekly abdominal pain and swelling of the hands and lips 
without urticaria, in association with trauma or psychological 
and physical stress. He visited the emergency room after a day 
of hard work during which he developed severe swelling of the 
lips, around the eyes, and of the right hand (the left hand was 
normal), without urticaria or dyspnea. The symptoms had pro-
gressed gradually over time. He had not taken any medications 
for his symptoms. He denied a history of drug use, including 
use of anti-hypertensive agents. The patient had a brother who 
had died of recurrent facial and laryngeal swelling 5 years earli-
The First Probable Case of Hereditary Angioedema in Vietnam
Khanh Bui Van, Doan Nguyen Van*
The Center of Allergy and Clinical Immunology, Bach Mai Hospital, Hanoi, Vietnam
er. The physical examination revealed a normal heart rate with 
regular rhythm, normal oxygenation, and normal blood pres-
sure. Diffuse swelling of his face, both lips, and right hand were 
noted (Figs. 1 and 2). He was treated with subcutaneous epi-
nephrine and systemic antihistamine and corticosteroid. One 
day later, the patient was better and was discharged.
In view of the clinical and family histories and clinical presen-
tation of this patient, we diagnosed HAE, despite a normal com-
plement C4 level. We could not measure the C1 esterase inhibi-
tor (C1-INH) level, as this test is not available in our country.
To prevent acute attacks of HAE, we started danazol 200 mg 
per day for 1 month, according to the Milan protocol for pro-
phylaxis at the outpatient clinic,
3,4,8-10 and observed no episodes 
of HAE during that month. We reduced the dose of danazol to 
100 mg per day. There were no episodes of swelling and no ad-
verse reactions for more than 2 months.
DISCUSSION
Landerman et al.
11 characterized HAE in 1962. The role of C1-
INH in regulating the contact system by inactivating both plas-
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Hereditary angioedema (HAE) is rare disorder due to C1-inhibitor deficiency (C1-INH) that are debilitating and may be life-threatening. HAE is a lack 
of consensus concerning diagnosis, therapy, and management, particularly in Vietnam. In this case report, we report a 40-year-old male patient with 
typical clinical symptoms and family history but he showed normal C4 level, and we could not measure C1q and C1-INH level. However, the diagno-
sis of HAE can be made based on typical clinical symptoms and the favorable prophylactic response to danazol treatment. Based on these findings, 
we suggest that he has type I HAE, although he showed normal C4 level.
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ma kallikrein and factor XIIa was elucidated in the 1970s and 
1980s.
11,13
HAE has a strong family history associated with a quantitative 
(type I) or qualitative (type II) deficiency of C1-INH caused by 
mutations of the C1-INH gene.
2 Type I HAE (85% of cases) pres-
ents with reduced C1-INH protein and function, while in type II 
(15% of cases), C1-INH has normal protein levels, but reduced 
function. Type III HAE, which presents with normal C1-INH 
protein and function, is an estrogen-dependent inherited form 
found mostly in females, with an otherwise unknown defect.
2,13
The diagnosis of HAE is based on the typical clinical symp-
toms, family history, and laboratory findings such as lower C4, 
C1q, and C1-INH levels. Our patient had typical clinical find-
ings with a positive family history, but a normal C4 level. Al-
though this might have been a laboratory error, some cases of 
HAE with a normal C4 level have been reported.
14 We could not 
measure the C1q or C1-INH level. In addition, the diagnosis of 
HAE can be based on a favorable clinical response to danazol 
treatment according to the Milan protocol for prophylaxis.
3,4,8-10 
Based on these findings, we postulate that our patient has type 
I HAE, even though he had a normal C4 level. He will require 
danazol therapy and long-term monitoring.
3,4,10
Approaches to the diagnosis and management of HAE vary 
among countries, as a full laboratory setting and some treat-
ments are not available in developing countries. Earlier treat-
ments were developed empirically and include the fibrinolysis 
inhibitors epsilon aminocaproic acid and tranexamic acid and 
attenuated androgens such as danozol.
3,4,10 In recent years, new 
agents such as C1 esterase inhibitor protein replacement prod-
ucts, a plasma kallikrein inhibitor, and a bradykinin receptor 
antagonist have been introduced.
15,16
To prevent acute attacks, we used danazol, which is the only 
drug available in Vietnam, based on results using danazol in 
HAE prophylaxis.
4,9,10,17 We prescribed danazol for 3 months and 
found that 100 mg of danazol daily prevented acute attacks of 
HAE in our patient.
In conclusion, we report the first probable case of HAE in 
Vietnam successfully treated with danazol. The diagnosis was 
based on the typical clinical symptoms, positive family history, 
and successful treatment with danazol. Further investigations 
are needed to identify more patients and define their clinical 
and laboratory findings in Vietnam.
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